An interventional study of Wireless NIRS in Hypoxic-Ischemic Encephalopathy, Congenital Heart Disease and Stroke Hemorrhagic, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hypoxia-Ischemia, Brain with a site in Canada — 10 open to participants now, 10 under way, none of them phase 3. Hypoxia-Ischemia, Brain · Canada.
Among the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 with no phase, and was the 18th registered.
261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.
Browse Hypoxia-Ischemia, Brain studies →10 of the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 1 days–1 days
University of Calgary · Sites in Canada
Pia Wintermark · Sites in Canada, United States
Ages 0 min–48 hrs
Hamilton Health Sciences Corporation · Sites in Canada
Ages 1 days–15 days
University of Michigan · Sites in Canada, United States, Australia and 2 more countries
Ages 2 days–17 yrs
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 156 interventional studies indexed under Hypoxia-Ischemia, Brain.
Median enrollment 42 across the 14 interventional studies, 50 across the 5 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 4 studies filed under Hypoxia-Ischemia, Brain — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypoxia-Ischemia, Brain with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07829887University of CalgaryCerebral Oximetry in Management of Post Cardiac Arrest | 2027-02 |
| NCT06985290Ipsita GoswamiDexmedetomidine Versus Morphine During Cooling Therapy in Neonates | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The wireless NIRS sensor will be placed on the participant's forehead, directly underneath the INVOS wired sensor. The wireless NIRS sensor will remain in place for 4 consecutive hours, over 2 consecutive days. As standard-of-care, nursing personnel removes all sensors at every care to evaluate skin and reduce the risk of pressure sores. The wireless NIRS device will be removed and reapplied at the same time, by the research team who will annotate what time the sensor was removed, replaced, and the condition of the skin. This will be used to correlate signal disconnection with sensor care (i.e., skin checks, sensor removal, etc.).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Wireless NIRS applied to participant's forehead.
Device: Wireless NIRS
Wireless NIRS applied to participant forehead.
Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.
Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.
Time frame: 6 months
Comparison of SpO2 and Heart Rate (HR) data between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).
Comparison of SpO2 and Heart Rate (HR) data between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).
Time frame: 6 months
Comparison of derived Heart Rate Variability (HRV) between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).
Comparison of derived Heart Rate Variability (HRV) between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).
Time frame: 6 months
Provide a questionnaire to capture the perspectives of clinicians and patients' parents/guardians regarding use of the wireless NIRS compared to wired NIRS device.
Provide a a custom study questionnaire to capture the perspectives of clinicians and patients' parents/guardians regarding use of the wireless NIRS compared to wired NIRS device. The questionnaire includes Likert-scale items, multiple-choice questions, and open-ended responses evaluating usability, perceived safety, accuracy, comfort, and acceptability. Responses will be summarized descriptively by questionnaire item.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 8 months after the start.
Of 46 non-industry interventional studies with no phase under Hypoxia-Ischemia, Brain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 63. This study's planned 8 months is below that.
Counting every sponsor, half of 47 studies reached it within 33 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →